Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Classification criteria of scleroderma].

Jean Cabane1,

  • 1Service de Médecine Interne, Hôpital Saint-Antoine, Paris. jean.cabane@sat.ap-hop-paris.fr

Presse Medicale (Paris, France : 1983)
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care.

Seminars in arthritis and rheumatism·2018
Same author

High Baseline Serum Clara Cell 16 kDa Predicts Subsequent Lung Disease Worsening in Systemic Sclerosis.

The Journal of rheumatology·2017
Same author

Comparing Inpatient Satisfaction Collected via a Web-Based Questionnaire Self-Completion and Through a Telephone Interview: An Ancillary Study of the SENTIPAT Randomized Controlled Trial.

Journal of medical Internet research·2017
Same author

Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial.

Arthritis care & research·2016
Same author

Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus.

PloS one·2016
Same author

Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience.

Rheumatology (Oxford, England)·2015

Scleroderma classification distinguishes localized and systemic forms, impacting prognosis and quality of life. Systemic scleroderma involves organ damage, while localized forms present aesthetic or functional issues.

Area of Science:

  • Rheumatology
  • Dermatology
  • Internal Medicine

Background:

  • Scleroderma classification is crucial for understanding disease prognosis and patient outcomes.
  • Distinguishing between localized and systemic scleroderma is fundamental.
  • Systemic scleroderma can affect multiple organs, significantly impacting patient quality of life.

Purpose of the Study:

  • To outline current classification criteria for scleroderma.
  • To differentiate between localized and systemic forms of scleroderma.
  • To describe subclassification within systemic scleroderma based on skin involvement.

Main Methods:

  • Review of existing scleroderma classification criteria.
  • Description of clinical features defining localized and systemic scleroderma.

Related Experiment Videos

  • Explanation of subclassification criteria including skin involvement, Raynaud's phenomenon, capillaroscopic findings, and autoantibodies.

    • Main Results:

    • Localized scleroderma primarily causes aesthetic or functional problems.
    • Systemic scleroderma presents significant functional and life-threatening risks due to organ involvement (lungs, heart, kidneys, etc.).
    • Systemic scleroderma is subclassified into "Cutaneous diffuse systemic scleroderma" (trunk involvement) and "limited systemic scleroderma" (defined by Raynaud's phenomenon, capillaroscopic abnormalities, and specific autoantibodies), with "Cutaneous limited systemic sclerosis" referring to distal skin involvement within the limited category.

    Conclusions:

    • The classification of scleroderma into localized and systemic forms remains clinically relevant.
    • Subclassification of systemic scleroderma aids in prognosis and management.
    • The term "CREST syndrome" is being phased out due to its lack of specificity.